Behavioural Pharmacology: 40+ Years of Progress, with a Focus on Glutamate Receptors and Cognition

Trevor W. Robbins,Emily R. Murphy

DOI: https://doi.org/10.1016/j.tips.2006.01.009

IF: 17.638

2006-01-01

Trends in Pharmacological Sciences

Abstract:Behavioural pharmacology is an interdisciplinary field at the intersection of several research areas that ultimately lead to the development of drugs for clinical use and build understanding of how brain functions enable cognition and behaviour. In this article, the development of behavioural pharmacology in the UK is briefly surveyed, and the current status and success of the field is highlighted by the progress in our understanding of learning and memory that has resulted from discoveries in glutamate receptor pharmacology allied to theoretical and methodological advances in behavioural neuroscience. We describe the original breakthrough in terms of the role of NMDA receptors in hippocampal-mediated spatial learning and long-term potentiation, and review recent advances that demonstrate the involvement of glutamate receptor in working memory, recognition memory, stimulus–response learning and memory, and higher cognitive functions. We also discuss the unique functions of NMDA receptors and the fundamental role of AMPA receptors in processes that are common to some of these forms of memory, including encoding, consolidation and retrieval. Behavioural pharmacology is an interdisciplinary field at the intersection of several research areas that ultimately lead to the development of drugs for clinical use and build understanding of how brain functions enable cognition and behaviour. In this article, the development of behavioural pharmacology in the UK is briefly surveyed, and the current status and success of the field is highlighted by the progress in our understanding of learning and memory that has resulted from discoveries in glutamate receptor pharmacology allied to theoretical and methodological advances in behavioural neuroscience. We describe the original breakthrough in terms of the role of NMDA receptors in hippocampal-mediated spatial learning and long-term potentiation, and review recent advances that demonstrate the involvement of glutamate receptor in working memory, recognition memory, stimulus–response learning and memory, and higher cognitive functions. We also discuss the unique functions of NMDA receptors and the fundamental role of AMPA receptors in processes that are common to some of these forms of memory, including encoding, consolidation and retrieval. Behavioural pharmacology (or psychopharmacology) is at a practical interface between the discovery of a novel pharmacological agent that acts on the CNS and the assessment of its utility, whether clinically as a therapeutic agent or for analytical purposes in psychology and neuroscience. Consequently, it is important to use precise methods for assessing and interpreting the effects of drugs on behaviour in humans and experimental animals. Adequate preclinical screening of drugs by pharmaceutical companies is essential for selecting candidates for expensive Phase II and III clinical trials. Furthermore, appropriately measuring behaviour is vital to test speculative hypotheses about the consequences of neuronal plasticity based on the effects of drugs observed in cultured tissue slices or the consequences of genetic manipulations for a particular neurotransmitter receptor. Behavioural pharmacology must thus be an integral component of many neuroscience research programmes. In this article, we review briefly the origins of behavioural pharmacology in the UK and as a particular example of its success show how it has been instrumental in understanding more precisely the role of glutamate as a neurotransmitter in the processes of neuronal plasticity, with particular reference to learning and memory. Behavioural pharmacology has flourished in the UK and worldwide, although it has evolved in several directions from different intellectual precursors and disciplines. The field derives from influences in pharmacology, psychiatry, neuroscience, ethology and several different traditions in psychology, each driven by a set of goals unique to the discipline. One of the main origins of behavioural pharmacology in the UK is work carried out in the Department of Pharmacology at University College London in the 1950s and 1960s. During this time, Roger Russell, the then Head of Department, encouraged Hannah Steinberg, in collaboration with Ian Stolerman and the late R. ‘Channi’ Kumar, to base their research programme on the behavioural effects of mixtures of stimulants and barbiturates in addition to opiates in experimental animals. Another major, but different, approach came from the field of psychiatry, where figures such as Max Hamilton and Alex Coppen had an interest in the treatment and aetiology of depression and other forms of mental illness. Hamilton constructed influential clinical scales for assessing both depression and anxiety in humans that are used today in evaluating the therapeutic efficacy of novel pharmacological agents. Both of these influences differed markedly from the development of behavioural pharmacology in the USA, which arose from a fusion of classic pharmacology and Skinnerian ‘operant’ psychology, as exemplified by the Harvard Medical School laboratory founded by Peter Dews, Roger Kelleher and Bill Morse. Although Harvard Medical School exerted an enormous influence over the methods used in the UK, in the late 1960s and early 1970s the late Jeffrey Gray at Oxford University and Susan Iversen at Cambridge University introduced two novel approaches to enrich behavioural pharmacology, the former depending on animal learning theory [1Gray J.A. The Neuropsychology of Anxiety. Oxford University Press, 1982Google Scholar], and the latter depending on a fusion between neuropsychology, neurochemistry and traditional behavioural pharmacology [2Iversen S.D. Iversen L.L. Behavioural Pharmacology.2nd Edn. Oxford University Press, 1981Google Scholar]. Both approaches focused on the study of how drugs worked on defined neural systems, using powerful behavioural paradigms; these advances continue to influence the work of current researchers. Iversen's move to the Merck, Sharp and Dohme Neuroscience Centre at Terlings Park, Harlow, UK is just one example of how academic scientists moving to the pharmaceutical sector enabled the application of evolving psychopharmacological methodology to the evaluation of new compounds. A landmark international CIBA symposium, ‘Animal Behaviour and Drug Action,’ held in London in 1963 and published a year later [3Steinberg, H. et al., eds (1964) Animal Behaviour and Drug Addiction, J&A Churchill LtdGoogle Scholar], contained several contributions from British psychopharmacology that reflected some of these origins. Reviewing the various contributions now, it is notable how contemporary many of the themes discussed at the meeting remain today. There were several chapters on the influence of drugs on memory (Jarvik) and learning (Bures and Russell), in addition to other current foci of research interest such as pharmacological interactions with frontal lobe functioning (Weiskrantz), amphetamine and neural reward mechanisms (Stein), and pharmacogenetics (Broadhurst). Furthermore, an entire section of the meeting was devoted to the relevance of the behavioural effects of drugs in animals and humans, thus presaging the current emphasis on translational neuroscience. What has changed since then? Many of the fundamental conceptual questions have remained the same, although they have become much more refined as a result of major advances in theory and methodology in experimental psychology and major discoveries (e.g. new neurotransmitter systems and multiplicities of novel receptor mechanisms) in neuropharmacology. Although learning and memory were important topics in the CIBA symposium and behavioural pharmacologists had begun to work out how best to study these functions, a possible role for glutamate in learning and memory was largely unsuspected. However, Jeffrey Watkins and colleagues (Bristol, UK) were, at that time, investigating the possible role of glutamate as a neurotransmitter [4Curtis D.R. et al.Chemical excitation of spinal neurones.Nature. 1959; 183: 611-612Crossref PubMed Scopus (188) Google Scholar], which had been a controversial issue since Hayashi's initial observations [5Hayashi T. Effects of sodium glutamate on the nervous system.Keio J. Med. 1954; 3: 183-192Crossref Scopus (171) Google Scholar] that central infusions of glutamate produced convulsions in experimental animals. In a recent review, Watkins [6Watkins J.C. I-Glutamate as a central neurotransmitter: looking back.Biochem. Soc. Trans. 2000; 28: 297-309Crossref PubMed Google Scholar] charts the stages by which glutamate gradually passed the stringent criteria for being a neurotransmitter substance, including structural and stereochemical specificity for actions at defined receptors, presynaptic release during axonal activity, the presence of an inactivation mechanism and the effect of specific antagonists on the production of excitatory postsynaptic potentials (EPSPs) by glutamate and the excitatory potential of the presumed neurotransmitter. Arguably the most impressive of all indications suggesting that glutamate is a neurotransmitter, however, came from behavioural pharmacology studies that demonstrated an intimate association between glutamate receptors and neuronal plasticity and complex behavioural functions, including learning and memory. These studies are reviewed here. The anti-epileptic agent MK801 (dizocilpine), with a hitherto unknown mechanism of action, was first discovered to be a non-competitive antagonist at NMDA receptors by the UK Merck group at Terlings Park [7Wong E.H.F. et al.The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist.Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 7104-7108Crossref PubMed Scopus (1679) Google Scholar] and was one of the many tools that became available from pharmaceutical companies in the 1980s for the study of the role of glutamate receptors in learning. This topic has thus been a prime example of the crucial and sustained contributions of academic and industrial behavioural pharmacologists and neuroscientists in the UK in what is now an increasingly collaborative, international enterprise. In the search for new drugs, this research field is now being linked to the modelling of hitherto pathologically elusive clinical disorders, including Alzheimer's disease and schizophrenia, in addition to less-obvious examples such as general anxiety disorder and drug addiction. A key breakthrough in understanding the neural basis of learning has been the realization that there are different types of memory subserved by different neural systems. Thus, there is a declarative form of long-term memory for episodes and facts that appears to be mediated mainly by structures of the medial temporal lobe. Other forms of memory, such as perceptuo-motor skills and some forms of Pavlovian and instrumental learning (including stimulus–response habits) (see Glossary) appear to devolve to several structures such as the motor cortex, dorsal and ventral striatum, and cerebellum [8Squire L.R. Memory and Brain. Oxford University Press, 1987Google Scholar]. By contrast, information that is used for only a short time and has to be kept ‘online’ for that purpose requires ‘working memory’ processes that implicate the prefrontal cortex, certain areas of the posterior cortex and the hippocampus [9Goldman-Rakic P.S. Circuitry of primate prefrontal cortex and regulation of behavior by representational memory.in: Plum F. Handbook of Physiology. American Physiological Society, 1987: 373-417Google Scholar]. However, although these dissociable forms of memory imply different forms of information processing in different brain regions, they might nevertheless be mediated by similar cellular and molecular mechanisms. Thus, it is increasingly appreciated that neuronal plasticity processes represented by cellular phenomena such as long-term potentiation (LTP) [and also long-term depression (LTD)] might underlie different forms of learning and memory. The neuropharmacology of LTP itself is complex and beyond the scope of this article but it is known to depend crucially on glutamate-mediated transmission. Classically, blockade of the NMDA subtype of glutamate receptors blocks LTP in slice preparations, as originally observed by the British neuropharmacologist Graham Collingridge while working with Hugh McLennan and colleagues [10Collingridge G.C. et al.J. Physiol. 1983; 334: 33-46PubMed Google Scholar, 11Bliss T.V. Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus.Nature. 1993; 361: 31-33Crossref PubMed Scopus (9607) Google Scholar] However, the salient observation for behavioural pharmacology, discovered by Richard Morris and colleagues at Edinburgh, was that blockade of NMDA receptors also inhibited certain forms of learning, at comparable doses of the NMDA receptor antagonist to those that inhibited LTP. Thus, Morris and colleagues [12Morris R.G. et al.Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5.Nature. 1986; 319: 774-776Crossref PubMed Scopus (2781) Google Scholar] showed that intracerebroventricular infusion of d-2-amino-5-phosphonopentanoic acid (AP-5), a competitive NMDA receptor antagonist, selectively impaired spatial learning in a water-maze escape task known to depend on the integrity of the hippocampus, but did not affect visual learning in the same maze. The remarkable observation was that this treatment did not have any effects on already established performance, indicating the effects were not obviously dependent on ancillary processes such as motivation, sensory perception or motor function. This selectivity of effect on task acquisition implies a direct action on associative learning mechanisms. The basic findings of the seminal study by Collingridge and McLennan have been substantiated by many subsequent demonstrations of impaired learning following manipulation of hippocampal NMDA receptors, whether by pharmacological experiments (generally employing rats) or genetic means (using mice). For example, Young and colleagues [13Young S.L. et al.NMDA process mediates anterograde amnesia of contextual fear conditioning induced by hippocampal damage: immunization against amnesia by context pre-exposure.Behav. Neurosci. 1994; 108: 19-29Crossref PubMed Scopus (218) Google Scholar] showed that NMDA receptor blockade in the hippocampus impaired the normal learning of associations between an environmental setting or context and an electric shock (‘contextual fear’). Although it was initially thought that there might be a special relationship between NMDA receptors and spatial or contextual learning that is dependent on the hippocampus, other studies quickly showed that the effects of NMDA receptor blockade on learning were more general and implicated both other neural structures and other behavioural assays. For example, deficits in the acquisition of both fear conditioning and appetitive conditioning to discrete stimuli in rats (i.e. approach to food-predictive cues) were shown to depend on NMDA receptors within the amygdala [14Burns L.H. et al.Intra-amygdala infusion of the N-methyl-D-aspartate receptor antagonist AP5 impairs acquisition but not performance of discriminated approach to an appetitive CS.Behav. Neural Biol. 1994; 61: 242-250Crossref PubMed Scopus (53) Google Scholar, 15Miserendino M.J.D. et al.Blocking of acquisition but not expression of conditioned fear- potentiated startle by NMDA antagonists in the amygdala.Nature. 1990; 345: 716-718Crossref PubMed Scopus (668) Google Scholar]. A form of stimulus–response learning that is dependent on the dorsal striatum (approaching cues that are predictive of reward) has also been shown to depend on NMDA receptors [16Packard M.G. Teather L.A. Double dissociation of hippocampal and dorsal-striatal memory systems by posttraining intracerebral injections of 2-amino-5-phosphonopentanoic acid.Behav. Neurosci. 1997; 111: 543-551Crossref PubMed Scopus (144) Google Scholar], and Dalley and colleagues [17Dalley J.W. et al.Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens.Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 6189-6194Crossref PubMed Scopus (184) Google Scholar] recently showed that the consolidation of appetitive approach behaviour to a conditioned stimulus predictive of food delivery was similarly dependent on NMDA (in addition to dopamine D1) receptors in the ventral striatum. Furthermore, DiCiano and colleagues [18Di Ciano P. et al.Differential involvement of NMDA, AMPA/Kainate, and dopamine receptors in the nucleus accumbens core in the acquisition and performance of Pavlovian approach behavior.J. Neurosci. 2001; 21: 9471-9477PubMed Google Scholar] showed that NMDA receptor antagonism in the core of the nucleus accumbens impaired acquisition of approach behaviour, whereas AMPA receptor antagonism impaired performance by disrupting discriminated approach. This growing catalogue of learning and memory deficits following NMDA receptor blockade has prompted several questions: what precise aspects of learning and memory are impaired, what is the role of other glutamate receptors (such as the AMPA subtype, which mediates fast depolarization by glutamate neurons, a prerequisite to NMDA receptor activation), and what therapeutic significance do these findings hold? For example, would it be feasible to enhance rather than impair learning or memory by manipulating glutamate-mediated transmission? New discoveries in behavioural pharmacology, enabled by the development of highly specific glutamatergic agents [19Kew J.N. Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology.Psychopharmacology (Berl.). 2005; 179: 4-29Crossref PubMed Scopus (596) Google Scholar], are beginning to answer these questions. The issue of which component of memory might be impaired concerns the processes implicated in initial encoding, later consolidation and storage, and the subsequent retrieval of the memory trace. These factors can be interrogated using so-called ‘one-trial’ memory tasks where (Figure 1) the agent of interest can be administered either before or just after initial learning and its effects on memory retrieval assessed by a subsequent retention test, possibly several days or more later. An agent that is only effective for a limited time-interval after training is said to affect consolidation rather than initial encoding of the trace. The agent can also be administered just before retention to test possible effects on memory retrieval (in addition to so-called ‘state-dependent’ effects, where the state change produced by the drug potentially acts as a memory-retrieval cue). Thus, the effects of blockade of NMDA receptors and other subtypes of glutamate receptors on different stages of memory can be determined. In one-trial ‘place memory’ tests, NMDA receptor blockade disrupted encoding and consolidation of the memory, but not retrieval [20Bast T. et al.Distinct contributions of hippocampal NMDA and AMPA receptors to encoding and retrieval of one-trial place memory.J. Neurosci. 2005; 25: 5845-5856Crossref PubMed Scopus (113) Google Scholar]. Some of these effects were delay dependent, in the sense that they varied with the delay to the retention test, with greater deficits at long retention intervals [21Steele R.J. Morris R.G. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5.Hippocampus. 1999; 9: 118-136Crossref PubMed Scopus (487) Google Scholar]. A similar pattern of findings has been found for learned fear of contexts [22Kim J.J. et al.Selective impairment of long-term but not short-term conditional fear by the N-methyl-D-aspartate antagonist APV.Behav. Neurosci. 1992; 106: 591-596Crossref PubMed Scopus (133) Google Scholar]. This implies that NMDA receptors have a selective role in the processes by which initially encoded events are made more permanent in long-term memory. By contrast, blockade of AMPA and kainate receptors with a selective antagonist such as LY326325 (see Chemical names) disrupts not only encoding but also consolidation and retrieval of spatial memories, showing that fast synaptic transmission via AMPA receptors is required more generally for all of these processes [23Riedel G. et al.Reversible neural inactivation reveals hippocampal participation in several memory processes.Nat. Neurosci. 1999; 2: 898-905Crossref PubMed Scopus (406) Google Scholar]. This selectivity of the role of NMDA compared with AMPA receptors has subsequently been demonstrated for some other forms of memory mediated by the hippocampus, such as event-place associations in the rat, which are more readily linked to the forms of episodic memory deficits that are shown by patients with Alzheimer's disease. In this example, rats were trained to associate flavours with particular places where they had found those flavours in single episodes (or trials). Again, blockade of NMDA receptors within the hippocampus impaired encoding but not retrieval of the flavour–place associations, whereas blockade of AMPA receptors using CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) disrupted encoding and retrieval [24Day M. et al.Glutamate-receptor-mediated encoding and retrieval of paired-associate learning.Nature. 2003; 424: 205-209Crossref PubMed Scopus (219) Google Scholar]. Parallel studies using an ingenious test of memory consolidation based on non-spatial, socially transmitted food preferences also shows that NMDA receptors are not simply implicated in spatial encoding, but are also implicated in non-spatial aspects of ‘declarative’ learning [25Roberts M. Shapiro M. NMDA receptor antagonists impair memory for nonspatial, socially transmitted food preference.Behav. Neurosci. 2002; 116: 1059-1069Crossref PubMed Scopus (26) Google Scholar].Chemical namesHA966:(+)-3-amino-1-hydroxypyrrolid-2-oneLY326325:(3RS,4aRS,6RS,8aRS)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydro-isoquinoline-3-carboxylic acid HA966:(+)-3-amino-1-hydroxypyrrolid-2-oneLY326325:(3RS,4aRS,6RS,8aRS)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydro-isoquinoline-3-carboxylic acid Most recently, the involvement of NMDA and AMPA receptors has been demonstrated in another aspect of memory – the ability to recognize objects, which is markedly impaired in Alzheimer's disease. There is now strong evidence that object recognition is more dependent on a specific region of the medial temporal lobe, the perirhinal cortex, than on the hippocampus [26Meunier M. et al.Effects on visual recognition of combined and separate ablations of the entorhinal and perirhinal cortex in rhesus monkeys.J. Neurosci. 1993; 13: 5418-5432PubMed Google Scholar, 27Murray E.A. Bussey T.J. Perceptual-mnemonic functions of the perirhinal cortex.Trends Cogn. Sci. 1999; 3: 142-151Abstract Full Text Full Text PDF PubMed Scopus (390) Google Scholar]. Recently, Winters and Bussey [28Winters B.D. Bussey T.J. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory.J. Neurosci. 2005; 25: 4243-4251Crossref PubMed Scopus (190) Google Scholar] have capitalized on this functional localization by administration of infusions of selective NMDA and AMPA receptor antagonists into the perirhinal cortex in rats at varying stages of performance of a visual object-recognition task. In this test, rats are allowed to interact with and explore a novel object before experiencing that now-familiar object again at a later time in conjunction with another object. Recognition memory can be inferred by the relative proportion of time the rats spend exploring the familiar and novel objects during a retention test carried out either a short or a longer time following the original presentation of the first object. The authors found that NMDA receptor blockade (using AP-5) impaired long- but not short-term object-recognition memory when infused before encoding the initial object (Figure 2a). This result suggests that NMDA receptors within the perirhinal cortex are not necessary for the initial perceptual encoding of the object but are required for the induction of synaptic plasticity required for the long-term storage of its trace. Moreover, NMDA receptor blockade soon after experience of the initial object also inhibited its subsequent recognition, showing that NMDA receptors are directly implicated in memory consolidation (Figure 2b). By contrast, NMDA receptor blockade immediately before the retention test had no effects on recognition memory, whereas AMPA receptor blockade (via CNQX) did disrupt retrieval, which parallels the findings for spatial memory in the hippocampus. AMPA receptor blockade also deleteriously affected all three stages of memory: encoding, consolidation and retrieval (Figure 2c). Thus, it appears that there is considerable generality in the glutamate mechanisms that mediate memory across not only domains (i.e. the nature of the memories), but also common memory processes, such as consolidation (Table 1).Table 1Involvement of NMDA and AMPA receptors in cognitive functionsaSymbols: (−), pharmacological antagonism; (+), direct or indirect agonism; (KO), genetic knockout model; ↑, function is improved; ↓, function is impaired; −, function is not affected., bSome effects are mediated in specific brain areas; see main text for details.Visual recognitionSpatial learningDeclarative memoryNMDA (−)AMPA (−)NMDA (−)AMPA (−)Encoding−↓−↓Consolidation↓↓↓↓Retrieval−↓−↓Appetitive and aversive conditioningExtinctionAssociative conditioningNMDA (−)AMPA (−)NMDA (−)NMDA (+)AMPA (−)Acquisition (encoding/consolidation)↓−↓↑−Performance (retrieval)−↓cDiscriminated approach to appropriate stimulus disrupted; a generalized deficit.Executive functionsNMDA (−)AMPA (−)AMPA (KO)Working memory↓↓dLow systemic doses impair performance only at long retention intervals.↓Discrimination learning↓XeGeneralized cognitive disruption.a Symbols: (−), pharmacological antagonism; (+), direct or indirect agonism; (KO), genetic knockout model; ↑, function is improved; ↓, function is impaired; −, function is not affected.b Some effects are mediated in specific brain areas; see main text for details.c Discriminated approach to appropriate stimulus disrupted; a generalized deficit.d Low systemic doses impair performance only at long retention intervals.e Generalized cognitive disruption. Open table in a new tab Another way of defining the roles of glutamate receptor subtype function in memory is to employ mutant mice with targeted genetic deletions. Thus, evidence from mice that lack the AMPA receptor subunit A (GluRA/GluR1) supports the role of fast synaptic transmission in working memory functions, as measured in a delayed alternation paradigm where the mice simply have to remember which arm they last visited in a T maze [29Schmitt W.B. et al.A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice.J. Neurosci. 2003; 23: 3953-3959PubMed Google Scholar]. The striking aspect of these data was that these mice were relatively unimpaired in a spatial task requiring longer-term memory and NMDA receptor involvement in the hippocampus, suggesting that different neuronal mechanisms within the hippocampus contribute to different (although probably interactive) types of information processing. One possible explanation for these possibly paradoxical results, given the normal close functional interdependence of NMDA and AMPA receptors, is that the targeted subunit deletion does not impair the function of the entire population of AMPA receptors such that NMDA receptor-mediated synaptic plasticity could be activated by a GluRA-independent mechanism. In previous studies, NMDA receptors had been implicated in spatial working memory functions in rodents, based on behavioural pharmacological evidence [21Steele R.J. Morris R.G. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5.Hippocampus. 1999; 9: 118-136Crossref PubMed Scopus (487) Google Scholar, 30Tonkiss J. Rawlins J.N. The competitive NMDA antagonist AP5, but not the non-competitive antagonist MK801, induces a delay-related impairment in spatial working memory in rats.Exp. Brain Res. 1991; 85: 349-358Crossref PubMed Scopus (54) Google Scholar]. The explosion in knowledge about the nature of the glutamate receptors involved in learning and memory and the regulation of glutamate-mediated transmission begs the question of how such information might be used to develop new agents for improving memory and cognitive function [19Kew J.N. Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology.Psychopharmacology (Berl.). 2005; 179: 4-29Crossref PubMed Scopus (596) Google Scholar]. The rather specific effects of NMDA receptor agents on the processes that link encoding to consolidation might encourage the further testing of this hypothesis by postulating selective enhancements with agonists. However, this strategy is weakened by the likelihood of serious side-effects (e.g. epilepsy and neurotoxicity) as a result of surplus activity of glutamate receptors. Some grounds for optimism are provided by effects reported on long-term memory recall in human volunteers by ‘AMPA-kine’ drugs that enhance excitatory glutamate transmission via their actions as positive allosteric modulators of the AMPA receptor [31Lynch G. Memory enhancement: the search for mechanism-based drugs.Nat. Neurosci. 2002; 5: 1035-1038Crossref PubMed Scopus (147) Google Scholar]. Additionally, interest has focused on partial agonists that facilitate N